Chardan Capital restated their neutral rating on shares of Esperion Therapeutics Inc. (NASDAQ:ESPR) in a research report report published on Saturday. Chardan Capital currently has a $12.50 price target on the biopharmaceutical company’s stock.

ESPR has been the subject of a number of other research reports. Barclays PLC set a $13.00 price objective on shares of Esperion Therapeutics and gave the stock a hold rating in a research report on Wednesday, August 31st. Stifel Nicolaus restated a buy rating and set a $64.00 price target on shares of Esperion Therapeutics in a research report on Thursday, September 22nd. Vetr downgraded shares of Esperion Therapeutics from a strong-buy rating to a buy rating and set a $12.60 price target for the company. in a research report on Tuesday, August 23rd. Credit Suisse Group AG restated a sell rating and set a $10.00 price target on shares of Esperion Therapeutics in a research report on Wednesday, July 6th. Finally, Royal Bank Of Canada downgraded shares of Esperion Therapeutics from an outperform rating to a sector perform rating and reduced their price target for the stock from $30.00 to $15.00 in a research report on Wednesday, June 29th. One research analyst has rated the stock with a sell rating, five have given a hold rating and eight have issued a buy rating to the company’s stock. Esperion Therapeutics presently has an average rating of Buy and an average target price of $28.51.

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics (NASDAQ:ESPR) opened at 12.05 on Friday. The company has a 50-day moving average price of $12.34 and a 200-day moving average price of $13.96. Esperion Therapeutics has a one year low of $9.58 and a one year high of $30.41. The company’s market capitalization is $271.73 million.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.16. During the same quarter in the previous year, the business earned ($0.55) earnings per share. Analysts expect that Esperion Therapeutics will post ($3.37) earnings per share for the current fiscal year.

Large investors have recently made changes to their positions in the company. Stifel Financial Corp raised its stake in shares of Esperion Therapeutics by 10.6% in the second quarter. Stifel Financial Corp now owns 15,017 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 1,438 shares in the last quarter. Pentwater Capital Management LP increased its position in shares of Esperion Therapeutics by 6.6% in the second quarter. Pentwater Capital Management LP now owns 1,518,000 shares of the biopharmaceutical company’s stock valued at $14,998,000 after buying an additional 94,000 shares during the last quarter. Parametric Portfolio Associates LLC increased its position in shares of Esperion Therapeutics by 315.0% in the second quarter. Parametric Portfolio Associates LLC now owns 42,903 shares of the biopharmaceutical company’s stock valued at $424,000 after buying an additional 32,566 shares during the last quarter. KCG Holdings Inc. acquired a new position in shares of Esperion Therapeutics during the second quarter valued at about $413,000. Finally, Senzar Asset Management LLC acquired a new position in shares of Esperion Therapeutics during the second quarter valued at about $2,171,000. Hedge funds and other institutional investors own 65.22% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

5 Day Chart for NASDAQ:ESPR

Receive News & Stock Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related stocks with our FREE daily email newsletter.